Last reviewed · How we verify

NCT04318054: Fibrovelis

Medical Benefit Evaluation of Ambulatory Activity Combining Rehabilitation and Therapeutic Education, Using an Intelligent Electric Bike for the Health, for the Effort Rehabilitation and the Quality of Life Improvement for Patients Suffering of Moderate Fibromyalgia (FIBROVELIS)

Status unknown NA Last updated 23 March 2020
What this trial tests

NA trial testing Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health. in Fibromyalgia in 56 participants. Status unknown.

Timeline
15 March 2020
Primary endpoint
30 March 2022
1 February 2023

Quick facts

Lead sponsorUniversity Hospital, Grenoble
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment56
Start date15 March 2020
Primary completion30 March 2022
Estimated completion1 February 2023

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

18 and older, any sex, with Fibromyalgia or Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to decrease the impact of the fibromyalgia on the daily quality of life of the patients suffering of moderate fibromyalgia at 6 months by the practice of an adapted physical activity coupled with therapeutic education workshop.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04318054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing